Showing 15,981 - 16,000 results of 106,807 for search '(( a de decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.80s Refine Results
  1. 15981
  2. 15982

    Video_5_Machine Learning of Motion Statistics Reveals the Kinematic Signature of the Identity of a Person in Sign Language.MP4 by Félix Bigand (11171898)

    Published 2021
    “…Posture normalization decreased the performance of the model, which nevertheless remained over five times superior to chance level. …”
  3. 15983

    Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus by Michael A. James (160308)

    Published 2012
    “…<div><p>Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L), resides in a region of chromosome 5 for which copy number gain has been found to be the most frequent genetic event in the early stages of non-small cell lung cancer (NSCLC). …”
  4. 15984

    Table 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  5. 15985

    Table 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  6. 15986
  7. 15987
  8. 15988
  9. 15989

    Nt5e is a trypsin-cleavable surface protein of <i>S. sanguinis</i> and affects platelet aggregation lag time. by Jingyuan Fan (159998)

    Published 2012
    “…All samples contained 15 µg of protein solubilized in 1% (w/v) SDS sample buffer. These samples were electrophoresed on a 10% gel, and stained with Coomassie Blue. …”
  10. 15990
  11. 15991

    Image_1_Exosomal miR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma.TIF by Jingxian Sun (6552710)

    Published 2021
    “…</p>Results<p>The exosomal miR-2276-5p in glioma patients had a significantly decreased expression, compared with non-glioma patients (p < 0.01). …”
  12. 15992
  13. 15993

    datasheet1_Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer.pdf by Abdul K. Siraj (9723983)

    Published 2020
    “…Identifying novel molecular therapeutic targets is highly needed in the management of EOC. Krupple-like factor 5 (KLF5), a zinc-finger transcriptional factor, is highly expressed in a variety of cancer types. …”
  14. 15994
  15. 15995
  16. 15996

    Table_1_Exosomal miR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma.doc by Jingxian Sun (6552710)

    Published 2021
    “…</p>Results<p>The exosomal miR-2276-5p in glioma patients had a significantly decreased expression, compared with non-glioma patients (p < 0.01). …”
  17. 15997
  18. 15998

    Image 5_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

    Published 2025
    “…R-bibliometrix, VOSviewer, and CiteSpace were employed to conduct quantitative analysis and visualize research trends and factors influencing QOL. Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”
  19. 15999
  20. 16000